©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 25, 2015; 6(14): 1259-1273
Published online Oct 25, 2015. doi: 10.4239/wjd.v6.i14.1259
Published online Oct 25, 2015. doi: 10.4239/wjd.v6.i14.1259
Erythropoietin and diabetes mellitus
Kenneth Maiese, Cellular and Molecular Signaling, Newark, NJ 07101, United States
Author contributions: Maiese K conceived, designed and wrote this article.
Supported by American Diabetes Association; American Heart Association; NIH NIEHS; NIH NIA; NIH NINDS; and NIH ARRA (to Maiese K).
Conflict-of-interest statement: The author declares no conflicts of interest.
Correspondence to: Kenneth Maiese, MD, Cellular and Molecular Signaling, 125 Main Street, Newark, NJ 07101, United States. wntin75@yahoo.com
Received: June 10, 2015
Peer-review started: June 11, 2015
First decision: August 16, 2015
Revised: August 25, 2015
Accepted: September 25, 2015
Article in press: September 28, 2015
Published online: October 25, 2015
Processing time: 137 Days and 11.9 Hours
Peer-review started: June 11, 2015
First decision: August 16, 2015
Revised: August 25, 2015
Accepted: September 25, 2015
Article in press: September 28, 2015
Published online: October 25, 2015
Processing time: 137 Days and 11.9 Hours
Core Tip
Core tip: Erythropoietin and the downstream signaling pathways of this cytokine that include protein kinase B, mechanistic target of rapamycin, Wnt signaling, Factors of the O class proteins, silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae), and AMP activated protein kinase offer new avenues for the development of novel treatments for diabetes mellitus and the complications of this disease.